We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Biogen Inc | NASDAQ:BIIB | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 4.27 | 2.00% | 217.78 | 217.78 | 219.00 | 217.88 | 213.11 | 215.30 | 1,144,156 | 01:00:00 |
From May 2021 to May 2024
By Matt Grossman
Biogen Inc. Thursday raised its full-year revenue forecast Thursday, but held constant its earnings outlook.
The Cambridge, Mass.-based drug maker said it now expects revenue of $10.65 billion to $10.85 billion in 2021. It had previously forecast revenue of $10.45 to $10.75 billion.
Biogen held steady its adjusted earnings forecast, targeting earnings of $17.50 to $19 a share.
Analysts surveyed by FactSet had been forecasting adjusted earnings of $18.50 a share on sales of $10.61 billion.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
July 22, 2021 08:01 ET (12:01 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Biogen Chart |
1 Month Biogen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
